Conoah and Nuocheng Jianhua jointly announced a licensing agreement with Prolium for CD20xCD3 bispecific antibodies

robot
Abstract generation in progress

On January 20th, JIN10 News reported that Connoa and NovaQuest jointly announced that the two companies and their joint venture have reached a licensing agreement with Prolium Bioscience, authorizing Prolium to develop and commercialize the CD20×CD3 bispecific antibody ICP-B02 (CM355). According to the protocol, Prolium will have the rights to develop, register, produce, and commercialize ICP-B02 in the global non-oncology field and the oncology field outside of Asia. NovaQuest and Connoa will receive a total payment of up to $520 million, including upfront and near-term payments, as well as additional payments for achieving clinical development, registration, and commercialization milestones, and both parties will receive a minority equity stake in Prolium. In addition, NovaQuest and Connoa will also receive tiered royalty payments based on future net sales of the product.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate app
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)